Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Anticoagulant: binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin; also inactivates factors IX, XI, XII, and plasmin.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes,As an anticoagulant for extracorporeal circuits and dialysis procedures
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Continuous IV infusion: 12-18 units/kg/hour, adjusted based on a PTT. Initial bolus of 60-80 units/kg may be given. Typical infusion rate for prophylaxis: 5,000 units subcutaneously every 8-12 hours.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal half-life: 1.5-2.5 hours (mean 1.7 h) for IV heparin; dose-dependent, increasing with higher doses (saturable clearance). In patients with renal impairment, half-life prolonged (up to 2-3 times).
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Primarily cleared by the reticuloendothelial system; partially metabolized by desulfation and depolymerization; renal excretion of metabolites.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: 50-60% as unchanged drug via urine; reticuloendothelial system: significant hepatic and splenic uptake with depolymerization; biliary: minor. Total clearance is dose-dependent due to saturable cellular binding.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Heparin binds to multiple plasma proteins: antithrombin III (ATIII) primarily (functional binding), but also to lipoproteins, histidine-rich glycoprotein, and platelet factor 4. Total protein binding: >90% (nonspecific binding).
Low protein binding; 0–11% bound, primarily to albumin.
0.05-0.07 L/kg (confined to plasma volume; ~5 L in 70 kg adult). Does not distribute into extravascular spaces. Increased Vd in pregnancy and obesity.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Subcutaneous: 20-30% (due to poor absorption, tissue binding, and first-pass degradation). IV: 100%. Not absorbed orally.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Not required; heparin is not renally cleared. However, monitor a PTT closely in patients with severe renal impairment (e GFR < 30 m L/min) due to increased bleeding risk.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Not recommended in severe hepatic impairment (Child-Pugh C) due to increased bleeding risk. In moderate impairment (Child-Pugh B), use with caution and monitor a PTT closely.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Loading dose: 75-100 units/kg IV over 10 minutes. Maintenance: Infants: 28 units/kg/hour; Children: 18-20 units/kg/hour; Adolescents: 18 units/kg/hour. Adjust to target a PTT.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Lower initial infusion rate (e.g., 10-12 units/kg/hour) due to increased sensitivity; monitor a PTT closely and reduce dose accordingly. Avoid subcutaneous if frail due to hematoma risk.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Spinal/epidural hematomas have occurred with neuraxial anesthesia or spinal puncture; monitor for signs of neurological impairment.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hemorrhage: monitor coagulation tests (a PTT, anti-Xa) and platelet counts,Heparin-induced thrombocytopenia (HIT): discontinue if HIT suspected,Hypersensitivity reactions: can cause anaphylaxis,Hyperkalemia: may suppress aldosterone, monitor potassium in renal impairment
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
History of heparin-induced thrombocytopenia (HIT),Active bleeding or bleeding disorders (e.g., hemophilia, thrombocytopenia),Severe uncontrolled hypertension,Recent major surgery or trauma with high bleeding risk,Hypersensitivity to heparin or pork products
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No significant food interactions. Maintain adequate hydration and a balanced diet. Avoid excessive alcohol consumption as it may increase bleeding risk.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Heparin does not cross the placenta and is not teratogenic; no known fetal risk in any trimester.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Heparin is not excreted into breast milk due to its high molecular weight; compatible with breastfeeding. M/P ratio: not applicable.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy requires close monitoring; dose adjustments may be needed due to increased plasma volume and clearance; anti-Xa monitoring recommended to achieve therapeutic levels.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Administer via continuous IV infusion using an infusion pump; do not give IM. Monitor a PTT 6 hours after initiation and adjust dose per nomogram. For prophylaxis, subcutaneous injection is preferred. Use with caution in patients with thrombocytopenia or history of HIT. Protamine sulfate is the reversal agent.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any signs of bleeding: unusual bruising, dark stools, blood in urine, bleeding gums.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed.,Inform all healthcare providers that you are on heparin.,Do not stop or change the dose without consulting your doctor.,If you miss a dose, contact your healthcare provider immediately.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Anticoagulant: binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin; also inactivates factors IX, XI, XII, and plasmin.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Continuous IV infusion: 12-18 units/kg/hour, adjusted based on a PTT. Initial bolus of 60-80 units/kg may be given. Typical infusion rate for prophylaxis: 5,000 units subcutaneously every 8-12 hours.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin does not cross the placenta and is not teratogenic; no known fetal risk in any trimester.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.